ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)

Completed

Conditions: Respiratory Tract Infection

Interventions: Drug: clarithromycin modified release 500 mg

First Posted Date: 2010-02-25

Last Posted Date: 2013-02-12

Lead Sponsor: Abbott

Target Recruit Count: 335

Registration Number: NCT01075204

Locations: 🇪🇬
Site Ref # / Investigator 51205, Cairo, Egypt
🇪🇬
Site Ref # / Investigator 51206, Tanta, Egypt
🇪🇬
Site Ref # / Investigator 50213, Helwan, Egypt

and more 9 locations

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Completed

Conditions: Severe Respiratory Syncytial Virus Infection

First Posted Date: 2010-02-25

Last Posted Date: 2011-03-23

Lead Sponsor: Abbott

Target Recruit Count: 2036

Registration Number: NCT01075178

Locations: 🇦🇹
Site Reference ID/Investigator# 7956, Vienna, Austria
🇫🇷
Site Reference ID/Investigator# 6261, Paris, France
🇫🇷
Site Reference ID/Investigator# 6244, Nantes, France

and more 34 locations

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

Completed

Conditions: HIV-1 Infections

Interventions: Drug: Lopinavir/ritonavir (Kaletra)

First Posted Date: 2010-02-24

Last Posted Date: 2011-08-03

Lead Sponsor: Abbott

Target Recruit Count: 98

Registration Number: NCT01074931

Locations: 🇨🇳
Site Reference ID/Investigator# 7244, Guangdong, China
🇨🇳
Site Reference ID/Investigator# 27864, Shanghai, China
🇨🇳
Site Reference ID/Investigator# 27865, Kunming, China

and more 2 locations

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: paricalcitol

First Posted Date: 2010-02-19

Last Posted Date: 2012-01-26

Lead Sponsor: Abbott

Target Recruit Count: 216

Registration Number: NCT01071070

Locations: 🇨🇳
Site Reference ID/Investigator# 35822, Wenzhou, China
🇨🇳
Site Reference ID/Investigator# 37722, Qingdao, China
🇨🇳
Site Reference ID/Investigator# 23485, Beijing, China

and more 9 locations

Remission in Subjects With Crohn's Disease, Open Label Extension

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab 40 mg eow or ew

First Posted Date: 2010-02-18

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 177

Registration Number: NCT01070303

Locations: 🇺🇸
Gastroenterology Associates of the East Bay, Berkeley, California, United States
🇺🇸
Gastroenterology Specialties, P.C., Lincoln, Nebraska, United States
🇺🇸
Atlanta Gastroenterology Assoc., Atlanta, Georgia, United States

and more 40 locations

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy Female Subjects

Interventions: Drug: ABT-263

First Posted Date: 2010-01-21

Last Posted Date: 2010-11-09

Lead Sponsor: Abbott

Target Recruit Count: 12

Registration Number: NCT01053520

Locations: 🇺🇸
Site Reference ID/Investigator# 23602, Waukegan, Illinois, United States

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ABT-436
Drug: Placebo

First Posted Date: 2010-01-15

Last Posted Date: 2010-11-03

Lead Sponsor: Abbott

Target Recruit Count: 36

Registration Number: NCT01050127

Locations: 🇺🇸
Site Reference ID/Investigator# 24849, Waukegan, Illinois, United States

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: ABT-126
Drug: Placebo for ABT-126

First Posted Date: 2010-01-06

Last Posted Date: 2010-11-02

Lead Sponsor: Abbott

Target Recruit Count: 16

Registration Number: NCT01043458

Locations: 🇺🇸
Site Reference ID/Investigator# 25423, Glendale, California, United States
🇺🇸
Site Reference ID/Investigator# 24322, San Antonio, Texas, United States

Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Itopride HCI 50 mg
Drug: Itopride HCI 100 mg
Drug: Placebo

First Posted Date: 2009-12-07

Last Posted Date: 2013-06-18

Lead Sponsor: Abbott

Target Recruit Count: 268

Registration Number: NCT01027260

Locations: 🇵🇰
Site Reference ID/Investigator# 21441, Karachi, Pakistan
🇵🇰
Site Reference ID/Investigator# 6130, Lahore, Pakistan
🇵🇰
Site Reference ID/Investigator# 5870, Karachi, Pakistan

and more 1 locations

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Phase 1

Completed

Conditions: Lymphoma
Chronic Lymphocytic Leukemia
Solid Tumors

Interventions: Drug: ABT-263
Drug: Ketoconazole

First Posted Date: 2009-11-30

Last Posted Date: 2010-12-20

Lead Sponsor: Abbott

Target Recruit Count: 12

Registration Number: NCT01021358

Locations: 🇺🇸
Site Reference ID/Investigator# 25068, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy